Skip to: Content
Skip to: Site Navigation
Skip to: Search
Newser - Current News - Breaking Stories

« Back to the grid | Next story »

Many Cancer Trials Go Unpublished: Study

Posted Sep 27, 08 4:45 PM CDT in Science & Health 

(Newser) – Fewer than 20% of cancer trial results are published in peer-review journals, a new study says. And industry-sponsored trials only achieve publication one time in 20. The reason? Scientists seeking success and media-hungry journals don't want to publish negative results, analysts say—even if they would aid other cancer studies.

"I knew that there was underpublication," but not at such high rates, study author Dr. Scott Ramsey told BusinessWeek. "We were really shocked by that." Studies that negated a drug's effects may have gone unpublished, he said, while positive ones were. Then "not only are we wasting lots of money, but we'd be giving patients false hopes about the value of the products."
Source: BusinessWeek

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon

Related Newser Stories

  • Drug Companies Hide Data From Docs

    Nov 26, 08 10:22 AM CST
    Drug Companies Hide Data From Docs Pharmaceutical companies aren't as upfront with doctors as they are with the government about their new products, a study finds. Though drug companies must provide the FDA with all of the data from clinical trials, related papers published in medical journals were found to omit info from 20% of the trials, and were often presented with a favorable twist, Wired reports.
    More »

  • How Congress Can Help Ted Kennedy

    Jun 11, 08 8:00 AM CDT
    How Congress Can Help Ted Kennedy Ted Kennedy has, at best, about two years to live. A drug exists that might extend his life, but Kennedy, and legions of other cancer sufferers, won’t get it because it hasn’t been through Phase III FDA trials. But congress could yet come to the rescue; a bill recently introduced in the Senate would give the terminally ill access to unproven treatments. More »

  • Despite Danger, FDA Sanctioned Artificial Blood Studies

    Apr 28, 08 1:50 PM CDT
    Despite Danger, FDA Sanctioned Artificial Blood Studies The Food and Drug Administration repeatedly approved experiments using artificial blood despite data showing the products to be dangerous, the Washington Post reports. Investigators from the National Institutes of Health found heart attack risk tripled and death increased by 30% for subjects in 16 studies testing five kinds of artificial blood, which, it is hoped, will ultimately provide alternative transfusions. More »

  • Deadly Heparin Found in 11 Nations

    Apr 22, 08 7:17 AM CDT
    Deadly Heparin Found in 11 Nations The FDA has traced a contaminated blood thinner from a Chinese factory to 11 countries, the New York Times reports. Severe reactions to the contaminated heparin have been linked to the deaths of 81 Americans, but it wasn't immediately clear if the drug may have triggered fatalities in other countries. Chinese officials have denied that the contamination caused any deaths and have demanded to be allowed to inspect the US plant where the heparin was packaged. More »

  • Doc: Merck Fudged Minutes of Meeting

    Apr 12, 08 9:33 AM CDT
    Merck's "minutes" of a meeting of heart doctors discussing cholesterol drug Vytorin were created a month after the meeting and distorted the viewpoints of the experts, one panel member changes. The drug company submitted the document to congressional investigators probing its two-year delay in releasing a report saying the drug didn't work any better than a much cheaper generic one, Bloomberg reports. More »

Many science journals refuse to publish negative results. "There are some journals which say, 'If you have negative results, we don't want to publish them,'" said one researcher. "It's dysfunctional."   (Index Stock)
The findings are particularly worrisome for cancer patients, given that many expensive new drugs have only modest survival benefits, adding at best a few months of life.   (Shutter Stock)
Experts say there are powerful incentives for researchers not to publish negative results, especially because scientists gain career advancement, money, and fame by making bold advances.   (Index Stock)
This clinical trial blackout is a huge problem in cancer research, BusinessWeek reports.   (Shutter Stock)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Related Threads

(1 of 2)

Tags

FDA • pharmaceutical companies • clinical trials • cancer prevention • journals


Loading...

Today's Most Popular

[ Stories ]

Threads

Loading...
SPONSORED NEWS ARCHIVE

Ensuring high-quality cancer care in the Medicare program.(ONCOLOGY NURSING... (Oncology Nursing Forum)

In the pink; Breast Cancer Awareness With October comes Breast Cancer Awareness... (The Journal (Newcastle, England))

Teaching Breast Health Early to Reduce Breast Cancer Mortality in D.C. (Targeted News Service)

Breast Cancer; Overview. (NWHRC Health Center - Breast Cancer)

Psychological Intervention May Improve Survival in Breast Cancer (Targeted News Service)

Failed lung cancer drug shows breast cancer promise (The Hindustan Times)

Meyskens Honored with AACR-Prevent Cancer Foundation Award for Excellence in... (US Fed News Service, Including US State News)

BOISE STATE UNIVERSITY CANCER RESEARCH BREAKTHROUGH MAY BE 'MAGIC BULLET' FOR... (US Fed News Service, Including US State News)

UNIVERSITY OF NEBRASKA MEDICAL CENTER EPPLEY CANCER CENTER RECEIVES $5.3 MILLION... (US Fed News Service, Including US State News)

Free home test for deadly disease Colon cancer second-leading cause of cancer... (News Sun, The (Waukegan, IL))


Other Science & Health Stories